Thrombopoietin (THPO) and the interaction with its receptor c-Mpl have a nonredundant role in platelet biogenesis and maintenance of the haematopoietic…

Although hypomethylating agents (HMA) have revolutionised the treatment of myelodysplastic syndromes (MDS), a significant proportion of patients either…

Transfusion-associated bacterial infection is a major risk of platelet transfusion and can be fatal. The storage requirements of platelet concentrates…

The humanised anti-CD20 antibody (Ab) rituximab (RTX) has significantly improved the prognosis of B cell non-Hodgkin’s lymphomas (BNHL). However, major…

First-line therapy for indolent non-Hodgkin’s lymphoma usually consists of a combination of rituximab-based chemoimmunotherapy. Historically, first-line…

Mycosis fungoides is the most common variant of cutaneous T cell lymphoma and frequently presents as early-stage disease with skin patches and plaques with an indolent course, but patients experience significant morbidity from itch and disfigurement.

Anaemia affects 1.6 billion people worldwide, with roughly 10% of these individuals affected by rare anaemias, of which 80% are hereditary. Hereditary…

Anaemia is the most widespread of the haematological disorders, affecting about one-third of the global population. Despite decades of public health…

Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. Specifically, it presents a…

Myelodysplastic syndromes (MDS) are highly heterogeneous clonal haematopoietic disorders. Allogeneic haematopoietic stem cell transplantation (HSCT)…